Brazilian Clinical and Microbiological Characterization of Acinetobacter spp. in Bloodstream Infections.
Coordenador do Projeto:
Ana Tereza Ribeiro de Vasconcelos
Laboratório Nacional de Computação Científica - LNCC
Fundação de Apoio ao Desenvolvimento da Computação Científica - FCC
Hospital das Clínicas de Porto Alegre
Universidade Federal de Sao Paulo - UNIFESP
Universidade de São Paulo - USP
Universidade de Taubaté
Hospital Base de Brasília
Universidade Federal do Pará - UFPA
Instituto Evandro Chagas - IEC
Centro de Patologia Clinica Natal Rio Grande do Norte
Hospital Israelita Albert Einstein São Paulo
Hospital Monsenhor Walfredo Gurgel Rio Grande do Norte
Fundación BioMerieux - Lyon
In recent years, Acinetobacter species have been increasingly described as a pathogen exhibiting high rates of carbapenem resistance. Therapeutic options for such infections have often required the use of older agents, such as polymyxins. In Brazil, we have observed high rates mortality amongst patients with bloodstream infections due to Acinetobacter spp., ranging from 39.6 to 65.5% . Oxa-carbapenemases have been described as the most frequent mechanism of carbapenem resistance, nevertheless oxacillinases weakly hydrolyses carbapenems and possibly other mechanisms of carbapenem resistance are involved.
Resistance to carbapenems adversely affects clinical outcomes, thus it is important to identify factors that alter clinical outcomes.
Here, we describe a proposal for creating BrasNET, a Brazilian network uniting basic and clinical scientists with the goal of studying clinically significant resistant pathogens. This network will initially focus on multi-drug resistant Acinetobacter spp. infections as this pathogen is widely spread in Brazilian hospitals.